Back

From obesity and sedentary lifestyle to energetic and metabolic failure: empagliflozin and semaglutide reverse mitochondrial and metabolic dysfunction in experimental HFpEF

30 August 2026 (09:40 - 09:50)
Organised by: Logo
Congress Presentation Part of: Risk factors and biomarkers in HFpEF Heart Failure with Preserved Ejection Fraction (HFpEF) ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Szilard Toth

University of Pecs, Pecs (Hungary)

5 More presentations in this session

Presentation thumbnail
Combined mitral and tricuspid regurgitation as a major determinant of rehospitalization in elderly patients with HFpEF
Assistant Professor D. Hadareanu (Craiova, RO)
Abstract Slides Video
Presentation thumbnail
Bone morphogenetic protein 10, a novel marker of atrial stress, is associated with incident heart failure in the general population
Mr T. Kok (Rotterdam, NL)
Abstract Slides Video
Presentation thumbnail
Gut microbiota-derived butyrate supports myocardial energetics and improves diastolic dysfunction in hypertensive HFpEF
Professor D. Mueller (Berlin, DE)
Abstract Slides Video
Presentation thumbnail
Systemic endothelial dysfunction and incident heart failure in a population-based cohort
Doctor A. Lebedeva (Greifswald, DE)
Abstract Slides Video
Presentation thumbnail
Galectin-3 binding protein is upregulated in heart failure with preserved ejection fraction and is modulated by endothelial nitric oxide synthase deficiency
Associate Professor R. Madonna (Pisa, IT)
Abstract Slides

Access the full session

Session thumbnail
Risk factors and biomarkers in HFpEF
Video

The Event

Event poster

ESC Congress 2026

30 August 2026 09:40 CET
You may be interested in
thumbnail
Congress Presentation
Effect of SGLT2i empagliflozin on left ventricular and mitochondrial function in a porcine model of anthracycline-induced cardiotoxicity
20 May 2023
thumbnail
Webinar
GLP-1 RAs and HFpEF: which HFpEF patients should now be receiving GLP-1 RAs?
15 December 2025
thumbnail
Congress Presentation
Comparative immune profiling in HFpEF: cross-species insights into inflammation and mitochondrial dysfunction
1 September 2025
thumbnail
Congress Presentation
Effect of SGLT-2 inhibitors on weight loss in HFrEF and HFpEF patients: meta-analysis of 14 thousand participants
20 May 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources